ALL SCTped 2012 FORUM - Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512657-24-00

Acronym

ALL SCTped FORUM

Enrollment

1108

Registered

2024-10-09

Start date

2014-03-27

Completion date

Unknown

Last updated

2025-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lymphoblastic Leukaemia

Brief summary

Stratum 1: Overall Survival (OS), Stratum 2: Event Free Survival (EFS)

Detailed description

Stratum 1: EFS, Stratum 2: OS, Stratum 1 and 2: Cumulative Incidence of Treatment-related mortality (TRM), Stratum 1 and 2: Cumulative Incidence of Relapse, Stratum 1 and 2: Toxicity: acute and late, Stratum 1 and 2: Acute Graft versus Host Disease (aGVHD) and chronic GVHD (cGvHD), Stratum 1 and 2: Secondary malignancies

Interventions

DRUGTREOSULFAN

DRUGCYCLOPHOSPHAMIDE

DRUGFLUDARABINE PHOSPHATE

DRUGTHIOTEPA

DRUGANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS

DRUGBUSULFAN

DRUGETOPOSIDE

DRUGRABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN

DRUGBLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion.

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Stratum 1: Overall Survival (OS), Stratum 2: Event Free Survival (EFS)	—

Secondary

Measure	Time frame
Stratum 1: EFS, Stratum 2: OS, Stratum 1 and 2: Cumulative Incidence of Treatment-related mortality (TRM), Stratum 1 and 2: Cumulative Incidence of Relapse, Stratum 1 and 2: Toxicity: acute and late, Stratum 1 and 2: Acute Graft versus Host Disease (aGVHD) and chronic GVHD (cGvHD), Stratum 1 and 2: Secondary malignancies	—

Countries

Austria, Belgium, Czechia, Denmark, France, Germany, Italy, Netherlands, Norway, Slovakia, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026